Adjuvant chemotherapy in older women with breast cancer: Who and what?

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 1996-2000

  Muss, Hyman B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CASE REPORT; FEMALE; GENE EXPRESSION ASSAY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SENTINEL LYMPH NODE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMORBIDITY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LIFE EXPECTANCY; LYMPHATIC METASTASIS; QUALITY OF LIFE; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; REFERRAL AND CONSULTATION; RISK ASSESSMENT; RISK FACTORS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905869480     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.8586     Document Type: Article

References (44)

1. National Cancer Institute: SEER Stat fact sheet: Breast cancer. http://seer.cancer.gov/statfacts/html/breast.html
2. Smith BD, Jiang J, McLaughlin SS, et al: Improvement in breast cancer outcomes over time: Are older women missing out? J Clin Oncol 29:4647-4653, 2011
3. Cho H, Klabunde CN, Yabroff KR, et al: Comorbidity-adjusted life expectancy: A new tool to inform recommendations for optimal screening strategies. Ann Intern Med 159:667-676, 2013
4. Centers for Disease Control and Prevention: National Center for Health and Statistics. Tables on trends in health and aging: Life expectancy. http://www.cdc.gov/nchs/fastats/lifexpec.htm
5. Walter LC, Covinsky KE: Cancer screening in elderly patients: A framework for individualized decision making. JAMA 285:2750-2756, 2001 (Pubitemid 32525372)
6. Ravdin PM: A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 23:43-50, 1996 (suppl 2)
7. Wishart GC, Bajdik CD, Dicks E, et al: PREDICT Plus: Development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 107:800-807, 2012
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
9. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996 (Pubitemid 26329660)
10. Barcenas CH, Niu J, Zhang N, et al: Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 32:2010-2017, 2014
11. Hoogerduijn JG, Buurman BM, Korevaar JC, et al: The prediction of functional decline in older hospitalised patients. Age Ageing 41:381-387, 2012
12. Fried TR, Bradley EH, Towle VR, et al: Understanding the treatment preferences of seriously ill patients. N Engl J Med 346:1061-1066, 2002 (Pubitemid 34984621)
13. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
14. Jones S, Holmes FA, O'Shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
15. Bonneterre J, Roché H, Kerbrat P, et al: Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23:2686-2693, 2005 (Pubitemid 46179458)
16. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
17. Swain SM, Tang G, Geyer CE Jr, et al: Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The NSABP B-38 trial. J Clin Oncol 31:3197-3204, 2013
18. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008 (Pubitemid 351549913)
19. Muss HB, Berry DA, Cirrincione CT, et al: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065, 2009
20. Shulman LN, Berry DA, Cirrincione CT, et al: Comparison of doxorubicin and cyclophosphamide versus single agent paclitaxel as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol (in press)
21. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999 (Pubitemid 30035956)
22. Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379:432-444, 2012
23. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081, 2005 (Pubitemid 40300281)
24. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23:8597-8605, 2005 (Pubitemid 46211501)
25. Muss HB, Berry DA, Cirrincione C, et al: Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B experience. J Clin Oncol 25:3699-3704, 2007 (Pubitemid 47372610)
26. Hamilton EP, Topping DL, Peppercorn JM, et al: Clinical impact of febrile neutropenia (FN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer. J Clin Oncol 31, 2013 (suppl 15; abstr 1076)
27. Lakhanpal R, Stuart-Harris R, Chan A, et al: A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer. J Clin Oncol 31:68s, 2013 (suppl; abstr 1079)
28. Freyer G, Campone M, Peron J, et al: Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: Results of an observational study. Crit Rev Oncol Hematol 80:466-473, 2011
29. Balducci L: Aging, frailty, and chemotherapy. Cancer Control 14:7-12, 2007
30. Extermann M, Boler I, Reich RR, et al: Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118:3377-3386, 2012
31. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
32. Hoppe S, Rainfray M, Fonck M, et al: Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol 31:3877-3882, 2013
33. Hurria A, Rosen C, Hudis C, et al: Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J Am Geriatr Soc 54:925-931, 2006 (Pubitemid 43847029)
34. Freedman RA, Pitcher B, Keating NL, et al: Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat 139:607-616, 2013
35. Jim HS, Phillips KM, Chait S, et al: Metaanalysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578-3587, 2012
36. Tofthagen C, Overcash J, Kip K: Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer 20:583-589, 2012
37. Yourman LC, Lee SJ, Schonberg MA, et al: Prognostic indices for older adults: A systematic review. JAMA 307:182-192, 2012
38. Perou CM, Parker JS, Prat A, et al: Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 11:718-719, 2010
39. Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783-2790, 2013
40. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006 (Pubitemid 46638957)
41. Biganzoli L, Wildiers H, Oakman C, et al: Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13:e148-e160, 2012
42. Jones EL, Leak A, Muss HB: Adjuvant therapy of breast cancer in women 70 years of age and older: Tough decisions, high stakes. Oncology (Williston Park) 26:793-801, 2012
43. Williams GR, Jones E, Muss HB: Challenges in the treatment of older breast cancer patients. Hematol Oncol Clin North Am 27:785-804, 2013
44. Wildiers H, Mauer M, Pallis A, et al: End points and trial design in geriatric oncology research: A joint European Organisation for Research and Treatment of Cancer-Alliance for Clinical Trials in Oncology-International Society of Geriatric Oncology position article. J Clin Oncol 31:3711-3718, 2013